Vasculitis - Comprehensive
Summary
Vasculitis is inflammation of blood vessels, which can affect vessels of any size (small, medium, or large) and any organ system. Think of vasculitis as your immune system attacking your own blood vessels—this inflammation damages the vessel walls, causing them to narrow or block, leading to reduced blood flow to organs and tissues. Vasculitis can be primary (disease itself) or secondary (caused by another condition like infection, drugs, or other autoimmune diseases). There are many types of vasculitis, classified by the size of vessels affected and the organs involved (e.g., giant cell arteritis affects large vessels, granulomatosis with polyangiitis affects small vessels, polyarteritis nodosa affects medium vessels). The presentation varies widely depending on the type and organs affected, but common features include fever, weight loss, fatigue, and organ-specific symptoms (kidney: blood/protein in urine, lung: cough/breathlessness, skin: rash, nervous system: numbness/weakness). The key to management is recognizing the pattern (symptoms, signs, organ involvement), confirming the diagnosis (blood tests, imaging, biopsy), classifying the type (essential for treatment), and providing appropriate treatment (usually immunosuppression—steroids, sometimes other immunosuppressants). Early recognition and treatment are essential to prevent permanent organ damage.
Key Facts
- Definition: Inflammation of blood vessels
- Incidence: Rare to uncommon (varies by type, 1-50 per 100,000)
- Mortality: Varies by type (5-30% if untreated, lower with treatment)
- Peak age: Varies by type (some in young adults, some in older adults)
- Critical feature: Multi-system involvement, inflammation of vessels
- Key investigation: Clinical assessment, blood tests (ANCA, etc.), imaging, biopsy
- First-line treatment: Immunosuppression (steroids, sometimes other agents)
Clinical Pearls
"Think multi-system" — Vasculitis usually affects multiple organ systems. If you see involvement of multiple systems (kidney + lung + skin, etc.), think vasculitis.
"ANCA is helpful but not diagnostic" — ANCA (anti-neutrophil cytoplasmic antibodies) is helpful for some types (granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis), but not all vasculitis is ANCA-positive. Don't rely on ANCA alone.
"Biopsy is often needed" — Biopsy of affected tissue (skin, kidney, lung, etc.) is often needed to confirm the diagnosis and classify the type. Don't skip this if diagnosis is uncertain.
"Type matters for treatment" — Different types of vasculitis need different treatments. Classifying the type is essential for appropriate treatment.
Why This Matters Clinically
Vasculitis is a serious condition that can cause permanent organ damage if not recognized and treated early. Early recognition (especially multi-system involvement), proper classification, and appropriate immunosuppressive treatment are essential. This is a condition that rheumatologists, nephrologists, and other specialists manage, and prompt treatment prevents organ damage.
Incidence & Prevalence
- Overall: Rare to uncommon (varies by type)
- Giant cell arteritis: Most common large vessel (10-20 per 100,000)
- Granulomatosis with polyangiitis: 2-5 per 100,000
- Trend: Stable (rare conditions)
- Peak age: Varies by type
Demographics
| Factor | Details |
|---|---|
| Age | Varies by type (GCA = older, GPA = middle-aged) |
| Sex | Varies by type (some female-predominant, some male) |
| Ethnicity | Some types more common in certain populations |
| Geography | No significant variation |
| Setting | Rheumatology, nephrology, internal medicine clinics |
Risk Factors
Non-Modifiable:
- Age (varies by type)
- Sex (varies by type)
- Genetics (some types)
Modifiable:
| Risk Factor | Relative Risk | Mechanism |
|---|---|---|
| Smoking | 2-3x | Some types (GPA) |
| Infection | 2-3x | Can trigger or cause secondary |
| Drugs | 2-3x | Can cause secondary |
Common Types
| Type | Vessel Size | Frequency | Typical Patient |
|---|---|---|---|
| Giant cell arteritis | Large | Most common large vessel | Older adults, female |
| Granulomatosis with polyangiitis | Small | 2-5 per 100,000 | Middle-aged |
| Microscopic polyangiitis | Small | 1-3 per 100,000 | Middle-aged |
| Eosinophilic granulomatosis with polyangiitis | Small | Rare | Middle-aged |
| Polyarteritis nodosa | Medium | Rare | Middle-aged |
| Other | Various | Rare | Various |
The Inflammation Mechanism
Step 1: Immune Dysregulation
- Autoimmune: Immune system attacks own vessels
- Trigger: May be triggered (infection, drugs, unknown)
- Result: Immune activation
Step 2: Vessel Inflammation
- Inflammation: Vessels become inflamed
- Damage: Vessel walls damaged
- Result: Vessel damage
Step 3: Vessel Narrowing/Blockage
- Narrowing: Vessels narrow (stenosis)
- Blockage: Vessels block (occlusion)
- Result: Reduced blood flow
Step 4: Organ Damage
- Ischemia: Organs don't get enough blood
- Infarction: Tissue death
- Dysfunction: Organ dysfunction
- Result: Organ damage
Step 5: Clinical Manifestation
- Symptoms: Organ-specific symptoms
- Signs: Organ-specific signs
- Result: Clinical presentation
Classification by Vessel Size
| Vessel Size | Types | Clinical Features |
|---|---|---|
| Large vessel | Giant cell arteritis, Takayasu arteritis | Headache, claudication, vision loss |
| Medium vessel | Polyarteritis nodosa, Kawasaki disease | Skin, nerves, gut |
| Small vessel | GPA, MPA, EGPA, IgA vasculitis | Kidney, lung, skin |
Anatomical Considerations
Organ Systems Affected:
- Kidney: Glomerulonephritis, renal failure
- Lung: Pulmonary hemorrhage, nodules
- Skin: Rash, ulcers
- Nervous system: Neuropathy, stroke
- Joints: Arthritis
- Eyes: Scleritis, uveitis
- GI tract: Ischemia, bleeding
Why Different Patterns:
- Vessel size: Determines which organs affected
- Type: Each type has characteristic pattern
Symptoms: The Patient's Story
Typical Presentation (Systemic):
Organ-Specific Symptoms:
History:
Signs: What You See
Vital Signs (May Be Abnormal):
| Sign | Finding | Significance |
|---|---|---|
| Temperature | May be elevated (low-grade fever) | Inflammation |
| Heart rate | Usually normal | Usually normal |
| Blood pressure | May be high (if kidney affected) | Hypertension |
| Respiratory rate | May be high (if lung affected) | Respiratory distress |
General Appearance:
Organ-Specific Signs:
| System | Signs |
|---|---|
| Kidney | Hypertension, edema, signs of renal failure |
| Lung | Crackles, signs of respiratory distress |
| Skin | Rash, ulcers, nodules, purpura |
| Nervous system | Neuropathy, weakness, stroke signs |
| Joints | Swelling, tenderness |
| Eyes | Redness, vision loss |
| GI tract | Abdominal tenderness, signs of ischemia |
Red Flags
[!CAUTION] Red Flags — Immediate Escalation Required:
- Signs of organ damage (kidney, lung, nervous system) — Needs urgent assessment, may need urgent treatment
- Rapid progression — Needs urgent assessment
- Signs of critical organ involvement — Needs urgent treatment
- Severe systemic symptoms — Needs urgent assessment
Structured Approach: ABCDE
A - Airway
- Assessment: Usually patent
- Action: Secure if compromised
B - Breathing
- Look: May have respiratory distress (if lung affected)
- Listen: May have crackles (if lung affected)
- Measure: SpO2 (may be low if lung affected)
- Action: Support if needed
C - Circulation
- Look: May have signs of organ damage
- Feel: Pulse (usually normal), BP (may be high if kidney affected)
- Listen: Heart sounds (usually normal)
- Measure: BP (may be high), HR
- Action: Monitor if organ damage
D - Disability
- Assessment: Neurological status (may have neuropathy, stroke)
- Action: Assess if neurological involvement
E - Exposure
- Look: Full examination, look for multi-system involvement
- Feel: Skin, joints, assess organs
- Action: Complete examination
Specific Examination Findings
Multi-System Examination:
- Kidney: Check BP, edema, signs of renal failure
- Lung: Auscultate, check for respiratory distress
- Skin: Look for rash, ulcers, nodules, purpura
- Nervous system: Check for neuropathy, weakness, stroke signs
- Joints: Check for swelling, tenderness
- Eyes: Check for redness, vision
- GI tract: Check for tenderness, signs of ischemia
Special Tests
| Test | Technique | Positive Finding | Clinical Use |
|---|---|---|---|
| ANCA | Blood test | May be positive | Some types (GPA, MPA, EGPA) |
| Biopsy | Tissue biopsy | Vessel inflammation | Diagnostic |
| Urinalysis | Urine test | Blood, protein | Kidney involvement |
First-Line (Bedside) - Do Immediately
1. Clinical Assessment (Most Important)
- History: Multi-system symptoms
- Examination: Multi-system signs
- Action: High suspicion if multi-system
2. Blood Tests (Essential)
- FBC: May show anemia, elevated white cells
- CRP, ESR: Usually elevated (inflammation)
- ANCA: If small vessel suspected
- Action: Supports diagnosis
Laboratory Tests
| Test | Expected Finding | Purpose |
|---|---|---|
| Full Blood Count | May show anemia, elevated white cells | Inflammation |
| CRP | Elevated | Inflammation |
| ESR | Elevated | Inflammation |
| ANCA | May be positive (GPA, MPA, EGPA) | Some types |
| Urinalysis | Blood, protein (if kidney affected) | Kidney involvement |
| Renal function | May be impaired (if kidney affected) | Kidney involvement |
Imaging
CT/MRI (If Needed):
| Indication | Finding | Clinical Note |
|---|---|---|
| Lung involvement | Nodules, hemorrhage | If lung affected |
| Vessel imaging | Vessel narrowing, inflammation | If large/medium vessel |
Biopsy (Essential for Diagnosis):
| Indication | Finding | Clinical Note |
|---|---|---|
| Affected tissue | Vessel inflammation | Diagnostic |
Diagnostic Criteria
Clinical Diagnosis:
- Multi-system involvement + signs of inflammation + biopsy showing vasculitis = Vasculitis
Type Classification:
- Vessel size: Large, medium, or small
- ANCA: Positive or negative
- Organ pattern: Which organs affected
- Biopsy: Specific features
Severity Assessment:
- Mild: Minimal organ involvement
- Moderate: Significant organ involvement
- Severe: Critical organ involvement
Management Algorithm
SUSPECTED VASCULITIS
(Multi-system involvement + signs of inflammation)
↓
┌─────────────────────────────────────────────────┐
│ CLINICAL ASSESSMENT │
│ • History (multi-system symptoms) │
│ • Examination (multi-system signs) │
│ • High suspicion if multi-system │
└─────────────────────────────────────────────────┘
↓
┌─────────────────────────────────────────────────┐
│ INVESTIGATIONS │
│ • Blood tests (FBC, CRP, ESR, ANCA) │
│ • Urinalysis (if kidney suspected) │
│ • Imaging (if needed) │
│ • Biopsy (essential for diagnosis) │
└─────────────────────────────────────────────────┘
↓
┌─────────────────────────────────────────────────┐
│ CLASSIFY TYPE │
│ • Vessel size (large, medium, small) │
│ • ANCA status │
│ • Organ pattern │
│ • Biopsy features │
└─────────────────────────────────────────────────┘
↓
┌─────────────────────────────────────────────────┐
│ TREATMENT │
├─────────────────────────────────────────────────┤
│ LARGE VESSEL (GCA, Takayasu) │
│ → High-dose steroids │
│ → May need other immunosuppressants │
│ │
│ SMALL VESSEL (GPA, MPA, EGPA) │
│ → High-dose steroids + cyclophosphamide or rituximab │
│ → Induction then maintenance │
│ │
│ MEDIUM VESSEL (PAN) │
│ → High-dose steroids + cyclophosphamide │
│ │
│ OTHER │
│ → As appropriate for type │
└─────────────────────────────────────────────────┘
↓
┌─────────────────────────────────────────────────┐
│ MONITOR & FOLLOW-UP │
│ • Monitor organ function │
│ • Monitor disease activity │
│ • Adjust treatment as needed │
│ • Long-term management │
└─────────────────────────────────────────────────┘
Acute/Emergency Management - The First Hour
Immediate Actions (Do Simultaneously):
-
Clinical Assessment
- History: Multi-system symptoms
- Examination: Multi-system signs
- Action: High suspicion if multi-system
-
Blood Tests (Urgent)
- FBC, CRP, ESR: Assess inflammation
- ANCA: If small vessel suspected
- Urinalysis: If kidney suspected
- Action: Supports diagnosis
-
Assess Organ Function
- Kidney: Check renal function
- Lung: Check respiratory function
- Other: As appropriate
- Action: Assess severity
-
Specialist Consultation
- Rheumatology: Essential
- Other specialists: As needed (nephrology, etc.)
- Action: Don't delay
-
Biopsy (If Needed)
- Affected tissue: Biopsy for diagnosis
- Action: Essential for diagnosis
Medical Management
Immunosuppression (Essential):
| Drug | Dose | Route | Duration | Notes |
|---|---|---|---|---|
| Prednisolone | 1mg/kg/day (max 60-80mg) | PO | Induction then taper | First-line |
| Cyclophosphamide | As appropriate | PO/IV | Induction | For severe (GPA, MPA, PAN) |
| Rituximab | As appropriate | IV | Induction | Alternative to cyclophosphamide (GPA, MPA) |
| Methotrexate | As appropriate | PO/SC | Maintenance | For maintenance |
| Azathioprine | As appropriate | PO | Maintenance | For maintenance |
Treatment by Type:
- GCA: High-dose steroids, may need methotrexate
- GPA/MPA: Steroids + cyclophosphamide or rituximab
- EGPA: Steroids, may need other agents
- PAN: Steroids + cyclophosphamide
Disposition
Admit to Hospital If:
- Severe: Critical organ involvement
- Needs IV treatment: If IV immunosuppression needed
- Monitoring: Needs close monitoring
Outpatient Management:
- Mild-moderate: Can be managed outpatient
- Regular follow-up: Monitor disease activity
Discharge Criteria:
- Stable: No critical organ involvement
- Treatment started: Treatment initiated
- Clear plan: For continued treatment, follow-up
Follow-Up:
- Regular: Monitor disease activity, organ function
- Long-term: Ongoing management
- Adjust treatment: As needed
Immediate (Days-Weeks)
| Complication | Incidence | Presentation | Management |
|---|---|---|---|
| Organ damage | 20-30% | Kidney, lung, nervous system damage | Immunosuppression, organ support |
| Renal failure | 10-20% | If kidney affected | Immunosuppression, may need dialysis |
| Pulmonary hemorrhage | 5-10% | If lung affected | Urgent immunosuppression, supportive care |
| Death | 5-30% (if untreated) | If severe, untreated | Prevention through early treatment |
Organ Damage:
- Mechanism: Ischemia from vessel damage
- Management: Immunosuppression, organ support
- Prevention: Early treatment
Early (Weeks-Months)
1. Usually Improves with Treatment (70-80%)
- Mechanism: Most respond to immunosuppression
- Management: Continue treatment
- Prevention: Early treatment
2. Persistent Organ Damage (20-30%)
- Mechanism: Permanent damage from ischemia
- Management: Ongoing management, may need organ replacement
- Prevention: Early treatment
Late (Months-Years)
1. Relapse (30-50%)
- Mechanism: Disease returns
- Management: Re-treat, may need long-term immunosuppression
- Prevention: Maintenance treatment
2. Chronic Organ Damage (20-30%)
- Mechanism: Permanent damage
- Management: Ongoing management
- Prevention: Early treatment
Natural History (Without Treatment)
Untreated Vasculitis:
- High mortality: 5-30% mortality (varies by type)
- Organ damage: Almost certain
- Poor outcomes: If not treated
Outcomes with Treatment
| Variable | Outcome | Notes |
|---|---|---|
| Remission | 70-80% | Most achieve remission with treatment |
| Mortality | 5-15% | Lower with treatment |
| Relapse | 30-50% | May relapse |
| Organ damage | 20-30% | May have permanent damage |
Factors Affecting Outcomes:
Good Prognosis:
- Early treatment: Better outcomes
- No organ damage: Better outcomes
- Type: Some types better prognosis
- Good response: Better outcomes
Poor Prognosis:
- Delayed treatment: Higher mortality, more organ damage
- Organ damage: Worse outcomes
- Type: Some types worse prognosis
- Poor response: Worse outcomes
Prognostic Factors
| Factor | Impact on Prognosis | Evidence Level |
|---|---|---|
| Early treatment | Better outcomes | High |
| Organ damage | Damage = worse | High |
| Type | Some types worse | Moderate |
| Response to treatment | Good response = better | Moderate |
Key Guidelines
1. EULAR Guidelines (2016) — EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. European League Against Rheumatism
Key Recommendations:
- Early recognition
- Appropriate immunosuppression
- Evidence Level: 1A
2. ACR Guidelines (2021) — American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody–associated vasculitis. American College of Rheumatology
Key Recommendations:
- Similar to EULAR
- Evidence Level: 1A
Landmark Trials
Multiple studies on immunosuppressive treatment, outcomes.
Evidence Strength
| Intervention | Level | Key Evidence | Clinical Recommendation |
|---|---|---|---|
| Immunosuppression | 1A | Multiple RCTs | Essential |
| Biopsy for diagnosis | 1A | Multiple studies | Essential |
What is Vasculitis?
Vasculitis is inflammation of blood vessels, which can affect vessels of any size and any organ system. Think of vasculitis as your immune system attacking your own blood vessels—this inflammation damages the vessel walls, causing them to narrow or block, leading to reduced blood flow to organs and tissues.
In simple terms: Your blood vessels have become inflamed, which can affect blood flow to different parts of your body. This is serious and needs treatment, but with proper treatment, most people do well.
Why does it matter?
Vasculitis is a serious condition that can cause permanent organ damage if not recognized and treated early. Early recognition and appropriate immunosuppressive treatment are essential. The good news? With proper treatment, most people achieve remission and do well.
Think of it like this: It's like your blood vessels becoming inflamed—this can affect blood flow to your organs, but with the right treatment, the inflammation can be controlled.
How is it treated?
1. Diagnosis:
- Assessment: Your doctor will assess you to see which organs are affected
- Tests: You'll have blood tests, urine tests, and sometimes a biopsy (small sample of tissue)
- Why: To confirm the diagnosis and see which type of vasculitis you have
2. Treatment:
- Immunosuppression: You'll get medicines to suppress your immune system (usually steroids, sometimes other medicines)
- Why: To stop your immune system from attacking your blood vessels
- Duration: Usually starts with high doses, then gradually reduced
3. Monitoring:
- Regular check-ups: You'll have regular check-ups to monitor your disease and organ function
- Adjust treatment: Your doctor will adjust your treatment as needed
- Why: To keep the disease under control and prevent organ damage
The goal: Control the inflammation, prevent organ damage, and help you achieve remission.
What to expect
Recovery:
- Treatment: Usually starts with high doses of medicines, then gradually reduced
- Remission: Most people achieve remission (disease under control) within months
- Relapse: Some people may have relapses (disease returns), which can be treated
After Treatment:
- Medicines: You'll need to take medicines long-term (usually)
- Monitoring: Regular monitoring of your disease and organ function
- Lifestyle: Usually can live normally, but need to take medicines and have regular check-ups
Recovery Time:
- Remission: Usually within months
- Long-term: Ongoing management
When to seek help
See your doctor if:
- You have symptoms that affect multiple systems (kidney, lung, skin, etc.)
- You have unexplained fever, weight loss, or fatigue
- You have symptoms that concern you
- You have a known diagnosis of vasculitis and develop new symptoms
Call 999 (or your emergency number) immediately if:
- You have severe symptoms (difficulty breathing, severe pain, etc.)
- You feel very unwell
- You have symptoms that concern you
Remember: If you have symptoms that affect multiple systems, especially if you have unexplained fever, weight loss, or fatigue, see your doctor. Vasculitis is serious, but with proper treatment, most people do well. Also, if you have a known diagnosis of vasculitis and develop new symptoms, see your doctor—this may indicate a relapse or complication.
Primary Guidelines
-
Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594. PMID: 27338776
-
Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366-1383. PMID: 34235894
Key Trials
- Multiple studies on immunosuppressive treatment, outcomes.
Further Resources
- EULAR Guidelines: European League Against Rheumatism
- ACR Guidelines: American College of Rheumatology
Last Reviewed: 2025-12-25 | MedVellum Editorial Team
Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists. This information is not a substitute for professional medical advice, diagnosis, or treatment.
"The Trap that Backfires."
- ANCA (Anti-Neutrophil Cytoplasmic Antibody) is not just a marker; it drives the disease.
- Mechanism:
- Priming: Infection causes cytokines (TNF) to prime neutrophils, moving antigens (MPO/PR3) to the cell surface.
- Binding: ANCA antibodies bind to these antigens.
- Activation: This activates the neutrophils inappropriately.
- NETosis: Neutrophils release Neutrophil Extracellular Traps (NETs) - webs of DNA and enzymes meant to catch bacteria. In vasculitis, these NETs damage the delicate endothelial lining of capillaries (especially in the kidney).
- Result: Necrotizing inflammation of small vessels (Pauci-immune).
"Tissue is the Issue."
1. Renal Biopsy (Gold Standard for Renal Vasculitis)
- Indication: Active urinary sediment (blood/protein) + rising creatinine.
- Technique: Percutaneous ultrasound-guided core biopsy (Left kidney lower pole).
- Findings:
- Crescentic Glomerulonephritis: Rupture of Bowman's capsule with proliferation of parietal cells (Crescents).
- Pauci-immune: Little staining for antibody/complement (distinguishes from Lupus).
2. Lung Biopsy
- Indication: Pulmonary nodules/infiltrates without renal signs.
- Technique:
- Trans-bronchial: Low yield.
- VATS (Video Assisted Thoracoscopic Surgery): Gold standard. Wedge resection.
- Findings (GPA): Granulomatous inflammation + Necrosis + Vasculitis.
3. Skin Biopsy
- Indication: Purpura.
- Technique: Punch biopsy (4-5mm). Feature: Leukocytoclastic Vasculitis (broken white cells).
"It looks like Vasculitis, but isn't." Treating these with steroids can be fatal.
- Infective Endocarditis:
- Features: Fever, Murmur, Splinter haemorrhages, Glomerulonephritis (Immune complex).
- Testing: Multiple sets of blood cultures + Echo. Rule #1: Exclude IE before diagnosing Vasculitis.
- Cholesterol Emboli:
- Features: "Blue Toe Syndrome", Renal failure after angiogram.
- Clue: Livedo reticularis + Hx of vascular procedure.
- Antiphospholipid Syndrome:
- Features: Clots + Livedo. (Thrombosis, not inflammation).
- Cocaine/Levamisole:
- Features: "Cocaine nose" (septal perforation) mimics GPA. Can cause positive ANCA.
Q1: Which vasculitis is associated with Hepatitis B? A: Polyarteritis Nodosa (PAN). (Classic association).
Q2: What is the specific ANCA pattern for GPA vs MPA? A:
- GPA (Wegener's) = c-ANCA (PR3).
- MPA = p-ANCA (MPO).
- (Note: Overlap exists).
Q3: What is "Pauci-immune"? A: "Few antibodies". On renal biopsy immunofluorescence, there is NO glowing green IgG/C3. This proves it is ANCA vasculitis, not Lupus (Full House) or Goodpasture's (Linear).
Q4: A patient on Cyclophosphamide develops blood in urine 5 years later. Diagnosis? A: Bladder Cancer (Transitional Cell Carcinoma). A major long-term risk of Cyclophosphamide.
Q5: Treatment for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)? A: Steroids are often sufficient for mild disease. Mepolizumab (Anti-IL5) is the new game-changer for the asthmatic component.
(End of Comprehensive Expansion)